Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?

Abstract

Treatment with remdesivir leads to a 35.9% reduction in LCS rate in follow-up. Severity of illness, need of ICU admission and length of hospital stay were factor associated with the persistence of PCS at 6 months of follow-up.